Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms.
Level 5 - mechanism / opinion, no new human data
Narrative review describing pharmacokinetic and pharmacological characteristics of a drug formulation without systematic review methodology.
PubMed 17515707 · doi:10.1097/MJT.0b013e31804c7292
What was done
This narrative review summarizes the clinical presentation, associated comorbidities, and pharmacological management of insomnia, focusing on the extended-release formulation of zolpidem (12.5 mg and 6.25 mg). It discusses pharmacokinetic, pharmacodynamic, and safety comparisons between 12.5 mg zolpidem extended-release and 10 mg immediate-release zolpidem based on early healthy-volunteer studies and clinical indications.
What was found
The abstract reports no numerical data or statistical comparisons. It describes zolpidem extended-release as a two-layer biphasic tablet that releases an initial layer immediately and a second layer more slowly, maintaining plasma concentrations longer than the immediate-release form. Time to maximum concentration (tmax) and elimination half-life (t1/2) were reported as similar between 12.5 mg extended-release and 10 mg immediate-release formulations. The review notes that the extended-release formulation reduces sleep latency, nocturnal awakenings, and wakefulness after sleep onset while increasing total sleep time.
Why it matters
The biphasic formulation provides a single pharmacological option designed to target both sleep onset and sleep maintenance symptoms without prolonging the elimination half-life relative to standard immediate-release zolpidem.
Limits
The abstract provides only narrative summary statements with no primary data, sample sizes, effect sizes, confidence intervals, or adverse event rates. As an unsystematic narrative review, it does not detail study selection criteria or evaluate risk of bias among the cited trials.
Cited by
- context The lowest commercially available dose of standard immediate-release Ambien (zolpidem) is 5 mg.